AstraZeneca raised its earnings guidance for the full year, after its margins were boosted by soaring sales of higher priced oncology and rare disease drugs and a drop in revenue from non-profit contracts for its Covid-19 vaccine.
阿斯利康(AstraZeneca)上调了全年营收指引，此前，由于该公司价格较高的肿瘤和罕见病药物销量飙升，以及新冠疫苗的非盈利合同收入下降，其利润率得到提高。
您已阅读17%（310字），剩余83%（1553字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。